Drug Interactions between Tivicay and Truvada
This report displays the potential drug interactions for the following 2 drugs:
- Tivicay (dolutegravir)
- Truvada (emtricitabine/tenofovir disoproxil)
Interactions between your drugs
No interactions were found between Tivicay and Truvada. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Tivicay
A total of 195 drugs are known to interact with Tivicay.
- Tivicay is in the drug class integrase strand transfer inhibitor.
- Tivicay is used to treat HIV Infection.
Truvada
A total of 245 drugs are known to interact with Truvada.
- Truvada is in the drug class antiviral combinations.
- Truvada is used to treat the following conditions:
Drug and food interactions
tenofovir food
Applies to: Truvada (emtricitabine / tenofovir disoproxil)
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References (1)
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
dolutegravir food
Applies to: Tivicay (dolutegravir)
Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.
References (1)
- (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.